Skip to main content
. 2020 Jun 7;6(6):e04092. doi: 10.1016/j.heliyon.2020.e04092

Table 2.

Baseline patient and tumor characteristics for all patients, those with a recognizable DIL on pathology and those without a DIL. Values are given as median (Inter-Quartile-Range) or number (%) as appropriate.

Characteristic All Patients [n = 455] DIL present [n = 396] No DIL present [n = 59] p-value∗
Age [years] 65.6 (60.3–69.8) 65.4 (60.1–69.7) 66.4 (61.2–71.5) 0.45
Baseline IPSS 6 (3–11) 6 (3–10) 8 (3–14) 0.12
Initial PSA [ng/mL]
7.1 (5.4–9.2)
7.0 (5.4–9.0)
7.4 (5.8–10.0)
0.28
T-Stage
0.09
 T1 329 (72%) 282 (71%) 47 (80%)
 T2a 89 (20%) 82 (21%) 7 (12%)
 T2b 28 (6%) 26 (7%) 2 (3%)
 T2c
9 (2%)
6 (2%)
3 (5%)

Gleason Grade Group
0.33
 1 77 (17%) 63 (16%) 14 (24%)
 2 322 (71%) 283 (71%) 39 (66%)
 3 56 (12%) 50 (13%) 6 (10%)
Biopsy Cores Sampled 11 (10–12) 10 (10–12) 12 (10–12) 0.002
Biopsy Cores Positive
4 (2–6)
4 (2–6)
4 (2–5.5)
0.84
Biopsy Positive Regions
 Base Cores Positive 1 (0–2) 1 (0–2) 1 (0–2) 0.14
 Mid Gland Cores Positive 2 (1–2) 2 (1–2) 1 (1–2) 0.98
 Apex Cores Positive 1 (0–2) 1 (0–2) 1 (0–2) 0.46
Use of ADT 84 (18%) 71 (18%) 13 (22%) 0.47

∗Mann-Whitney-Wilcoxon or Fisher's exact test was used as appropriate between no DIL and DIL groups.